Mhd Louai Manini1, Michael Camilleri2, Rayna Grothe3, Carlo Di Lorenzo4. 1. Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. manini.mhd@mayo.edu. 2. Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 3. Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 4. Division of Pediatric Gastroenterology, Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA.
Abstract
BACKGROUND: Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Little is known about the role and dosing of pyridostigmine in pediatric GI motility disorders. METHODS: We present a case series of children with GI dysmotility managed with oral pyridostigmine. Patients' diagnoses include chronic intestinal pseudo-obstruction, gastroparesis with delayed small bowel transit, chronic constipation with failure to thrive, and prolonged ileus after pelvic surgery with chronic opioid use. RESULTS: Pyridostigmine was effective and safe in all cases. Pyridostigmine decreased abdominal distention, increased bowel movement frequency, and improved enteral feeding tolerance. Effective dosing ranged between 0.25-2.0 mg/kg/day. One patient experienced cramping abdominal pain while on pyridostigmine, but pain resolved after medication was discontinued. CONCLUSION: We found oral pyridostigmine to be helpful in children with different GI motility problems. Pyridostigmine should be considered in such patients when other treatment interventions have not been beneficial.
BACKGROUND:Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Little is known about the role and dosing of pyridostigmine in pediatric GI motility disorders. METHODS: We present a case series of children with GI dysmotility managed with oral pyridostigmine. Patients' diagnoses include chronic intestinal pseudo-obstruction, gastroparesis with delayed small bowel transit, chronic constipation with failure to thrive, and prolonged ileus after pelvic surgery with chronic opioid use. RESULTS:Pyridostigmine was effective and safe in all cases. Pyridostigmine decreased abdominal distention, increased bowel movement frequency, and improved enteral feeding tolerance. Effective dosing ranged between 0.25-2.0 mg/kg/day. One patient experienced cramping abdominal pain while on pyridostigmine, but pain resolved after medication was discontinued. CONCLUSION: We found oral pyridostigmine to be helpful in children with different GI motility problems. Pyridostigmine should be considered in such patients when other treatment interventions have not been beneficial.
Authors: Adil E Bharucha; Phillip Low; Michael Camilleri; Erica Veil; Duane Burton; Yogish Kudva; Pankaj Shah; Tonette Gehrking; Alan R Zinsmeister Journal: Gut Date: 2012-06-07 Impact factor: 23.059
Authors: G Di Nardo; C Di Lorenzo; A Lauro; V Stanghellini; N Thapar; T B Karunaratne; U Volta; R De Giorgio Journal: Neurogastroenterol Motil Date: 2016-09-29 Impact factor: 3.598
Authors: Jessica Robinson-Papp; Alexandra Nmashie; Elizabeth Pedowitz; Mary Catherine George; Sandeep Sharma; Jacinta Murray; Emma K T Benn; Steven A Lawrence; Josef Machac; Sherif Heiba; Seunghee Kim-Schulze; Allison Navis; Bani Chander Roland; Susan Morgello Journal: J Neurovirol Date: 2019-05-16 Impact factor: 2.643
Authors: Giovanni Di Nardo; Federica Viscogliosi; Francesco Esposito; Vincenzo Stanghellini; Maria Pia Villa; Pasquale Parisi; Alessia Morlando; Girolamo Caló; Roberto De Giorgio Journal: J Neurogastroenterol Motil Date: 2019-10-30 Impact factor: 4.924